Income statement, balance sheet and cash flow statement for the last 6 fiscal years, taken from the XBRL data Century Therapeutics, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
5.2
2.24
6.59
109
Research and development
39.7
75.6
97.2
92.7
107
95.7
General and administrative
9.5
19.2
31.9
34.7
33.2
24
Operating expenses
53.9
94.9
139
149
145
126
Operating income
-53.9
-94.9
-134
-147
-138
-17.3
Interest expense
0.38
1.28
1.02
0.54
Interest income
12.7
13
7.35
Other non-operating income
0.32
-0.9
2.99
11.8
13.4
7.62
Pre-tax income
-53.6
-95.8
-131
-135
-125
-9.65
Income tax
0.04
0.09
1.88
1.79
-0.07
Net income
-53.6
-95.8
-131
-137
-127
-9.58
EBITDA
-52.5
-91.1
-125
-134
-125
-4.17
EPS, basic
-9.34
-3.86
-2.27
-2.30
-1.61
-0.14
EPS, diluted
-9.34
-3.86
-2.96
-2.30
-1.61
-0.14
Shares, basic (weighted)
5.74
24.8
57.8
59.3
78.6
86.6
Shares, diluted (weighted)
5.74
24.8
32.4
59.3
78.6
86.6
Balance sheet
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
27.2
56.4
84.3
47.3
58.4
61.9
Short-term investments
48.5
166
231
125
131
55.3
Other current assets
0.26
0.25
4
1.57
4.76
3.66
Total current assets
78.8
228
320
177
194
121
Property, plant and equipment
15.4
58
82.8
71.7
62.1
50
Lease right-of-use assets
9.39
11.9
28.9
20.4
28.7
16.1
Intangible assets
34.2
34.2
Long-term investments
1.05
136
51.9
89.1
30.8
Total assets
107
437
487
361
353
224
Accounts payable
8.08
7.6
5.45
2.74
3.08
4.77
Accrued liabilities
3.13
4.45
7.06
6.5
7.7
4.63
Deferred revenue
7.15
4.37
109
Short-term debt
1.04
6.5
Total current liabilities
12.1
15.7
29.8
17.8
130
20.2
Long-term debt
9.64
8.9
3.74
Lease liabilities
11.7
14.6
38.7
46.7
49
40.2
Total liabilities
33.4
41.1
184
176
192
64.8
Total debt
9.64
10.4
10.4
Paid-in capital
218
785
824
840
943
951
Retained earnings
-292
-388
-519
-656
-782
-792
Other comprehensive income
-0
-0.65
-2.46
0.11
0.32
0.03
Shareholders' equity
-106
396
303
185
161
159
Total equity
-106
396
303
185
161
159
Total liabilities and equity
107
437
487
361
353
224
Shares outstanding
5.74
44.8
55
60.3
85.8
87.5
Cash flow statement
FY2021
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-53.6
-95.8
-131
-137
-127
-9.58
Depreciation and amortization
1.4
3.75
8.44
13
13.3
13.1
Stock-based compensation
0.88
4.66
10.7
14.6
12.7
6.84
Deferred income tax
0.01
-0
0.87
-0.07
Change in payables
2.06
-1.85
-4.79
-2.36
-1.47
1.56
Cash from operations
-41.3
-89
14.1
-88.3
-110
-104
Capital expenditures
-9.83
-45
-30.6
-13.7
-0.15
-0.85
Purchases of investments
-49.9
-330
-254
-209
-120
-51.2
Sales and maturities of investments
41.7
76.7
271
284
177
160
Cash from investing
-22.8
-298
-13.1
61.1
47.5
108
Debt repaid
-10.2
Stock issued
0.21
0.35
0.52
0.14
0.17
Cash from financing
47.7
418
27.2
-9.73
74.6
0.17
Net change in cash
30.4
28.1
-36.9
11.9
3.8
Free cash flow
-51.1
-134
-16.6
-102
-110
-105
Interest paid
0.21
0.97
1.1
0.59
Income taxes paid
0.01
2.52
0.51
3.89
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $1.67 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Return on equity (ROE)
-47.3%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-38.3%
Net income / average total assets.
Return on invested capital (ROIC)
-50.6%
Approximation: operating income x (1 - tax rate) / average (total debt + equity - cash). Tax rate is the effective rate when between 0% and 50%, else 21%.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
1,557.0%
Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y
175.9%
Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value growth, 1y
-1.5%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-19.3%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets growth, 1y
-36.7%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
-22.8%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
15.9%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
10.1%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
38.8%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
72.1%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
8.28x
Current assets / current liabilities.
Quick ratio
7.94x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
7.94x
(Cash + short-term investments) / current liabilities.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
FCF per share
-$0.43
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$0.42
Cash from operations / diluted weighted shares.
Book value per share
$1.29
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/B
1.30x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
1.53x
Market cap / tangible book value, when positive.
FCF yield
-29.1%
Free cash flow / market cap.
Earnings yield
-36.3%
Net income / market cap (the inverse of P/E).
What was Century Therapeutics, Inc.'s revenue in fiscal 2025?
Century Therapeutics, Inc. reported revenue of $109.2M for fiscal 2025, 1,556.8% higher than the year before.
Was Century Therapeutics, Inc. profitable in fiscal 2025?
No. It reported a net loss of $9.6M.
How much free cash flow did Century Therapeutics, Inc. generate in fiscal 2025?
Cash from operations of $103.9M minus capital expenditures of $848.0K left free cash flow of -$104.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.